with FAC followed by paclitaxel. The pathologic complete response rate was significantly higher in those treated with FAC and paclitaxel (25% vs. 10%). The addition of paclitaxel led to improvement in progression-free (27 vs. 18 months) and median
Search Results
Inflammatory Breast Cancer
Holly Dushkin and Massimo Cristofanilli
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up . Ann Oncol 2020 ; 31 : 1306 – 1319 . 32739407 6. Park SB , Kwok JB , Asher R , Clinical and genetic predictors of paclitaxel neurotoxicity based on
Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer
Merel J.M. van Velzen, Marieke Pape, Mirjam A.G. Sprangers, Jessy Joy van Kleef, Bianca Mostert, Laurens V. Beerepoot, Marije Slingerland, Elske C. Gootjes, Ronald Hoekstra, Lonneke V. van de Poll-Franse, Nadia Haj Mohammad, and Hanneke W.M. van Laarhoven
aid them in decision-making regarding therapy. A high prevalence of CIPN in this population can be expected, because the most often used treatment regimens in GEC contain either paclitaxel, docetaxel, carboplatin, and/or oxaliplatin. 3 , 15
Treating Triple-Negative Breast Cancer: Where Are We?
Aki Morikawa and Andrew D. Seidman
. Microtubule-Targeting Agents Based on the TNBC subtypes, the basal-like types are postulated to respond well to taxanes because of their expression of proliferation genes. 21 Efficacy of paclitaxel specifically for TNBC (compared with non-TNBC) has been
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
Virginia G. Kaklamani and William J. Gradishar
(standard dose), or a combination of both agents (lapatinib, 1000 mg/d plus standard trastuzumab dosing). 7 The anti-HER2 therapy was administered alone for the first 6 weeks, at which point weekly paclitaxel was added to the assigned anti-HER2 therapy for
Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location
Angela Jain, Paula D. Ryan, and Michael V. Seiden
this point showed that liver metastases had completely calcified without evidence of new disease ( Figure 1 ). With the goal of increasing tumor response, weekly paclitaxel was added to trastuzumab. Over 6 weeks, the CEA continued to trend down to 496
Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance
Shankar Sellappan, Adele Blackler, Wei-Li Liao, Emily O'Day, Peng Xu, Sheeno Thyparambil, Fabiola Cecchi, Todd Hembrough, and Daniel V.T. Catenacci
now 358 and 266 amol/mcg, respectively ( Figure 1B ). After bleeding was controlled, treatment was initiated with paclitaxel, trastuzumab, and lapatinib, a dual HER2/EGFR tyrosine kinase inhibitor. 8 – 10 This regimen led to continued tumor reduction
EGFR-Mutant Non–Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing
Ammar Sukari, Misako Nagasaka, and Erin Wakeling
chemotherapy with carboplatin and paclitaxel. She then presented to our institution. Given the deferring histology, we obtained NGS on the adrenal gland biopsy, which reported similar molecular signature with EGFR exon 19 deletion (E746 del) and T790M. She
Part 1: Abstracts From the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care™
Nanoparticle Albumin Bound (nab)-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide (AC) in Triple-Negative Breast Cancer Jasgit C. Sachdev, a Jessica Snider, a Lee Schwartzberg, b Robyn Young, c Furhan Yunus, a Jeffrey Allen, a
EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance
Michael Cecchini, Jeffrey Sklar, and Jill Lacy
advances in the treatment of metastatic PDAC with 5-fluorouracil (5FU), irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel, median survival remains <1 year. 2 , 3 Moreover, second-line treatment options are of limited